Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 150.52M | 123.76M | 113.65M | 111.23M | 108.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.52M | 123.76M | 113.65M | 111.23M | 108.65M |
| Cost of Revenue | 9.83M | 6.18M | 5.69M | 4.33M | 3.36M |
| Gross Profit | 140.69M | 117.58M | 107.95M | 106.90M | 105.29M |
| SG&A Expenses | 123.74M | 110.00M | 100.04M | 97.94M | 91.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -469.20K | -2.81M | -2.47M | -2.37M | -2.20M |
| Total Operating Expenses | 185.56M | 163.00M | 150.52M | 146.68M | 132.77M |
| Operating Income | -35.04M | -39.24M | -36.87M | -35.45M | -24.12M |
| Income Before Tax | -44.31M | -47.03M | -43.15M | -40.87M | -27.20M |
| Income Tax Expenses | 1.12M | 2.69M | 841.90K | 1.74M | 693.00K |
| Earnings from Continuing Operations | -45.43 | -49.73 | -44.00 | -42.61 | -27.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.43M | -49.73M | -44.00M | -42.61M | -27.90M |
| EBIT | -35.04M | -39.24M | -36.87M | -35.45M | -24.12M |
| EBITDA | -34.70M | -38.94M | -36.62M | -35.25M | -23.95M |
| EPS Basic | -0.85 | -0.93 | -0.82 | -0.79 | -0.52 |
| Normalized Basic EPS | -0.52 | -0.55 | -0.50 | -0.48 | -0.32 |
| EPS Diluted | -0.85 | -0.93 | -0.82 | -0.79 | -0.52 |
| Normalized Diluted EPS | -0.52 | -0.55 | -0.50 | -0.48 | -0.32 |
| Average Basic Shares Outstanding | 214.70M | 214.69M | 214.69M | 214.28M | 213.85M |
| Average Diluted Shares Outstanding | 214.70M | 214.69M | 214.69M | 214.28M | 213.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
